[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.75.176. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 1,426
Citations 0
In This Issue of JAMA Neurology
November 2014

Highlights

JAMA Neurol. 2014;71(11):1343. doi:10.1001/jamaneurol.2013.4176
Research

Flint and colleagues determine whether inpatient statin use in intracerebral hemorrhage (ICH) is associated with improved outcomes and whether the cessation of statin use is associated with worsened outcomes. Detailed electronic medical and pharmacy records were analyzed to explore the association between inpatient statin use and outcomes. Among patients hospitalized for ICH, inpatient statin users were more likely than nonusers to be alive 30 days after ICH and were more likely than nonusers to be discharged to their home or an acute rehabilitation facility. Inpatient statin use is associated with improved outcomes after ICH, and the cessation of statin use is associated with worsened outcomes after ICH.

Editorial

Continuing Medical Education

Huh and coauthors evaluate the efficacy and safety of mycophenolate mofetil (MMF) treatment in patients with neuromyelitis optica spectrum disorder (NMOSD). They examined results from 59 patients with NMOSD (24 with neuromyelitis optica and 35 with a limited form of the disease) who were treated with MMF (1000-2000 mg/d). This treatment induced reduction of relapse frequency, stabilized or improved disability, and was well tolerated in patients with NMOSD.

Editorial

Continuing Medical Education

Cohen and colleagues evaluate the relationship between walking speed measured by the Timed 25-Foot Walk (T25-FW) and the Physical Component Summary (PCS) score of the 36-Item Short Form Health Survey (SF-36) to better understand the clinical meaning of T25-FW walking speed in multiple sclerosis (MS). They retrospectively analyzed data from 3 clinical trials that included T25-FW and SF-36 scores as outcomes in patients with MS. Patients had secondary-progressive MS and an Expanded Disability Status Scale score of 3.5 to 6.5 or relapsing-remitting MS and an Expanded Disability Status Scale score of 0 to 5.0. Among all 2549 patients from the 3 trials, walking speed and SF-36 PCS score at baseline were significantly correlated (n = 2333; r = 0.48; P < .001).

Agrawal and colleagues elucidate the molecular cause of a neuromuscular disease among a family in which 4 members, a mother and her 3 sons, were affected. Two of 4 affected members manifested nemaline myopathy, a common subtype of congenital myopathy, while the other 2 had a nonspecific myopathy. NEFL mutations are known to cause Charcot-Marie-Tooth disease in humans and motor neuron disease in mice.

Clinical Review & Education

Thomas and coauthors identified articles through a search of PubMed references from March 2005 through January 2014. They note that advances in the understanding of the molecular biology of glioblastoma are being rapidly translated into innovative clinical trials, capitalizing on improved genomic, epigenetic, transcriptional, and proteomic characterization of glioblastomas as well as host factors. They report that glioblastoma is an aggressive tumor with heterogeneous molecular features and complex host interactions.

×